partnershipSanthera licences vamorolone rights to Catalyst PharmaceuticalsLatest News Santhera Pharmaceuticals Holding has exclusively granted the rights to commercialise its Duchenne muscular dystrophy drug vamorolone in North America to Catalyst Pharmaceuticals Inc. Read more 20 June 2023 https://european-biotechnology.com/wp-content/uploads/2024/04/Santhera.jpg 640 1184 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2023-06-20 09:21:192024-07-10 07:09:22Santhera licences vamorolone rights to Catalyst Pharmaceuticals